A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis Who Have Previously Received ALN-TTRSC
Phase of Trial: Phase II
Latest Information Update: 30 May 2017
At a glance
- Drugs Revusiran (Primary)
- Indications Amyloidosis; Cardiomyopathies
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 10 Oct 2016 Dosing discontinued; Follow-up of patients for safety
- 18 Jul 2016 Planned End Date changed from 1 May 2017 to 1 Mar 2017.
- 18 Jul 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Feb 2017.